Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $415
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $408 to $415.
December 11, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $408 to $415.
The increase in price target by Barclays reflects a positive outlook on Vertex Pharmaceuticals, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100